Use Case 1
GLP-1 Initiation Assessment
Trigger: Provider initiating GLP-1 receptor agonist therapy
1.Retrieve patient record (meds, conditions, BMI, A1c, eGFR, family history)
2.Run Module 1 Black Box screening (MTC or MEN2 personal and family history)
3.Screen for pancreatitis history, severe GI disorders, and gastroparesis
4.Verify renal function for agent-appropriate dosing
5.Apply FDA-labelled starting dose and titration schedule for selected agent
6.Generate patient counseling sheet (injection technique, GI symptom expectations, red flags)
7.Schedule first follow-up at week 4 for tolerability check
8.Set up A1c and weight trajectory tracking
✓
Provider initiates GLP-1 therapy with full contraindication screening and patient education in a single workflow.
Use Case 2
Black Box Contraindication Screening
Trigger: MTC, MEN2, or thyroid cancer signal detected in patient or family history
1.Pause assessment and request specific histology if diagnosis is generic 'thyroid cancer'
2.Apply absolute contraindication if MTC or MEN2 confirmed
3.Generate PharmD escalation packet with full family-history context
4.Recommend non-GLP-1 alternatives appropriate to the indication
5.Document hard-stop reason and class-wide contraindication note in record
6.Mark assessment as terminated at Module 1
7.Flag the patient record to prevent future GLP-1 re-prescription
✓
Black Box contraindication caught at the point of decision with audit-ready documentation.
Use Case 3
Titration & Tolerability Monitoring
Trigger: Scheduled GLP-1 follow-up visit
1.Pull current dose, weeks at dose, GI symptom log, weight trajectory, and A1c
2.Compare progress against FDA-labelled efficacy and tolerability benchmarks
3.Recommend hold, escalate, or de-escalate dose based on tolerability and response
4.Flag plateau or sub-response cases for second-agent consideration
5.Screen for pancreatitis red flags (severe abdominal pain, persistent vomiting)
6.Update patient counseling for the next phase
7.Generate visit summary with rationale for the dose decision
✓
Titration paced to tolerability with response-driven decision making.
Integrations
EHR / FHIR R4 API (Epic, Cerner, athenahealth)
FDA Prescribing Information Reference
Pharmacy Claims (adherence verification)
Lab Integration (A1c, lipase, eGFR)
PharmD Escalation Workflow
Patient Counseling Document Generation
Industries
healthcare
See It In Action
A sample conversation with this agent
Starting semaglutide for Sarah Kim—Type 2 diabetes, A1c 8.2, BMI 34.
Pulling Sarah's record. T2DM × 5 years, on metformin 1000mg BID, no prior GLP-1 exposure. Module 1 contraindication screening—critical step before initiation: I need to verify there's no personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Her chart family history shows no thyroid cancer; let me confirm with you and document. Renal function (eGFR 78) and pancreatic history are clear. Recommended starting dose per FDA labelling: semaglutide 0.25mg weekly × 4 weeks, then 0.5mg, with GI-tolerability check before each escalation. Generating the patient counseling sheet on injection technique, GI side effects, and the symptom-warning checklist (severe abdominal pain → pancreatitis red flag).
Her sister was just diagnosed with thyroid cancer. Should we continue?
HARD STOP—pause and clarify. The Black Box contraindication is specifically medullary thyroid carcinoma (MTC) or MEN2, not all thyroid cancers. Most thyroid cancers (papillary, follicular) are NOT contraindications. I need the histology of her sister's diagnosis before we can proceed. If MTC or MEN2: discontinue immediately, consult endocrinology, do not re-challenge with any GLP-1 class agent. If papillary, follicular, or other non-medullary: Sarah can continue, no Black Box trigger. Routing this to PharmD with the family-history flag and the histology question. I won't generate any further titration guidance until the histology is documented.
Sarah's down 18 pounds in 6 months but A1c only dropped from 8.2 to 7.6. Is this working?
Module 4 disease control review. Weight loss of 18 lb (~8% of starting weight) is squarely in the FDA-labelled efficacy range for semaglutide—that part is working. The A1c response is below the typical 1.0–1.5% reduction expected at 6 months. Two questions to investigate: (1) titration progress—is she at the target 1.0mg or 2.0mg dose, or held at a sub-therapeutic dose for tolerability? (2) adherence—pharmacy claims show consistent fills, so probably not adherence. If she's not at target dose, the plan is to escalate cautiously with GI tolerability checks. If she's at target dose and A1c is stalled, this signals beta-cell exhaustion—adding a second agent (SGLT2 inhibitor for cardiorenal benefit, or basal insulin) is indicated. Routing to PharmD for the dose-vs-add-on decision.